Skip to content

Swift Treatment using transcranial magnetic stimulation and Outcome Prediction in Depression

Swift Treatment using transcranial magnetic stimulation and Outcome Prediction in Depression - STOP-D

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00028014
Enrollment
44
Registered
2022-02-04
Start date
2021-02-04
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33 F31

Interventions

Group 1: Accelerated intermittent theta-burst stimulation (aiTBS), 5 sessions per day, 5 days Group 2: Historic control: standard intermittend theta-burst stimulation (iTBS), 1 session per Day, 4 week

Sponsors

Universitätsklinikum der RWTH Aachen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Adult wmen and women between 18 and 80 years-old with a current nonpsychotic depression (either as part of a major depressive disorder or bipolar disorder) according to ICD-10; at least 20 points on the 17-item Hamilton-scale at baseline; nonresponse to at least one antidepressant; stable psychiatric medication in the last two weeks; sufficient German language skills; written informed consent; in case of legal guardianship also informed consent of the legal guardian

Exclusion criteria

Exclusion criteria: Known seizure disorder (epilepsia) or confounding neurological disease, dementia or cognitive impairment; other somatic disease that interfers with the investigation or has an effect on the investigated parameters; current alcohol or drug abuse Drogen-, Alkohol- oder Schmerzmittelabusus; pregnancy or lactation; electromagnetic or metallic medical devices in or connected to the body (e.g., pacemakers, drug pumps, cochlea implants); metal in the body (e.g., screws due to fractures, shards of metal, metal prostheses, non-MR-compatible vascular clips); previous heart and/or brain surgery; widespread tattoos; previous treatment with TMS

Design outcomes

Primary

MeasureTime frame
Montgomery-Åsberg Depression Rating Scale (MADRS) score change from baseline to immediately after intervention

Secondary

MeasureTime frame
Number of responders and remitters in the ‘aiTBS’ arm vs. the ‘iTBS’ arm at the end of treatment; score changes from before to after intervention on scales measuring severity of depression (HRSD-17; BDI-II) as well as suicidal tendency (C-SSRS)

Countries

Germany

Contacts

Public ContactKatrin Sakreida

Uniklinik RWTH Aachen

ksakreida@ukaachen.de+49 241 80-80233

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026